The reduction therapy has been approved. Recently, the National Medical Products Administration (NMPA) approved the marketing application of Novo Nordisk's developed and produced Novo Nordisk (Smegglutide Injection for long-term weight management) in China, which is considered to open up a new pattern of obesity treatment in China. From a medical perspective, obesity is a chronic and complex disease caused by the interaction of biological, genetic, social, psychological, and environmental factors. As early as 1997, the World Health Organization (WHO) defined obesity as a disease. According to the obesity standards of the Chinese population, the proportion of obese adults in China is 16.4%. Obesity not only hinders the normal function of patients' body parts, but also is associated with more than 200 diseases, such as cardiovascular diseases, certain types of cancer, type 2 diabetes, etc. Therefore, obesity is often regarded as the source of all diseases. As the world's first and currently the only weekly preparation of glucagon like peptide-1 receptor agonist (GLP-1RA) for long-term weight management. The approval of this innovative drug will provide a new healthy weight management plan for overweight and obese patients (with an initial BMI greater than or equal to 30; or between 27 and 30, and at least one weight related comorbidities). From the perspective of its mechanism of action, Novoyin can help patients reduce hunger, increase satiety, and reduce food craving. In addition, through gene recombination technology, Nuoheying extended its half-life to 7 days and achieved once a week administration while maintaining a high homology of 94% with human GLP-1. Professor Chen Wei from the Clinical Nutrition Department of Peking Union Medical College Hospital stated that in response to the limited number of drugs approved for the treatment of obesity in China over the past 20 years, new medical weight loss drugs can provide patients with safe, effective, and convenient treatment options. This has a profound impact on the clinical practice of obesity and related diseases, and will open a new chapter in the treatment of obesity in China. The STEP series of global large-scale clinical studies by Novo&Young included approximately 25000 overweight and obese subjects. The experimental results showed that compared with placebo, the average weight loss after treatment with Novoying reached 17% (16.8kg) and could last for 16 months. In addition, NovoPlus can bring multiple health benefits besides weight loss, including reducing waist circumference, reducing visceral fat, improving blood lipids, and delaying the early progress of diabetes. (Lai Xin She)